Data From QIN-Breast

This collection contains longitudinal PET/CT and quantitative MR images collected for the purpose of studying treatment assessment in breast cancer in the neoadjuvant setting. Images were acquired at three time points: prior to the start of treatment (t1), after the first cycle of treatment (t2), and either after the second cycle of treatment or at the completion of all treatments (prior to surgery) (t3). The PET/CT images were acquired with a support device built in-house to allow the patient to be in the prone position to facilitate registration with the MRI data. The value of this collection is to provide clinical imaging data for the development and evaluation of quantitative imaging methods for treatment assessment early in the course of therapy for breast cancer. Data is provided by Vanderbilt University, PI Dr. Thomas E. Yankeelov. PET/CT data were acquired with a GE Discovery STE scanner (GE Healthcare, Waukesha, WI, USA). A low-mAs CT scan was acquired for attenuation correction of the emission data. The acquisition parameters for the transmission CT scan were the following: the tube current was 80 mAs for a 70-kg patient and scaled accordingly for all patients, the tube voltage was 120 KVp, and the pitch was 1.675/1. The activity of FDG administered was approximately 370 MBq (10 mCi) for a 70-kg patient and scaled according to weight. FDG was administered intravenously via an antecubital vein contra-lateral to the affected breast. After 60 min, emission data was collected in 3D mode for 2 min per bed position. The emission scan was first collected in the prone position over the breast only, and then in the supine position from the skull to mid-femurs. Standard-of-care supine images and research prone images were acquired at times t1 and t3, while only the prone images were acquired at t2. The MRI data consist of diffusion-weighted images (DWIs), dynamic contrast-enhanced (DCE) images, and multi-flip data for T1-mapping. The MRIs were obtained using a dedicated 16-channel bilateral breast coil at 3.0T (Philips Achieva with the MammoTrak table). DWIs were acquired with a single-shot spin echo (SE) echo planar imaging (EPI) sequence in three orthogonal diffusion encoding directions (x, y, and z). For 14 patients, b = 0 and 500 s/mm2, TR/TE = 2500 ms/45 ms Δ = 21.4 ms, δ = 10.3 ms and 10 signal acquisitions were acquired. For 19 patients, b = 0 and 600 s/mm2, TR/TE = “shortest” (range = 1800 - 3083 ms/43 - 60 ms) Δ = 20.7 - 29 ms, δ = 11.4 - 21 ms and 10 signal acquisitions were acquired. For four patients, b = 50 and 600 s/mm2 for two patients), TR/TE = “shortest” (range = 1840 - 3593 ms/43 - 60 ms) Δ = 20.6 - 29 ms, δ = 11.5 - 21 ms and 10 signal acquisitions were acquired. Prior to the DCE-MRI acquisition, data for constructing a T1 map were acquired with an RF-spoiled 3D gradient echo multi-flip angle approach with ten flip angles from 2 to 20 degrees in 2o increments. For both the T1 map and DCE scans, TR = 7.9 ms, TE = 4.6 ms, and the acquisition matrix was 192x192x20 (full-breast) over a sagittal square field of view (22 cm2) with slice thickness of 5 mm. For the DCE study, each 20-slice set was collected in 16 seconds at 25 time points for just under seven minutes of dynamic scanning. A catheter placed within an antecubital vein delivered 0.1 mmol/kg (9 – 15 mL, depending on patient weight) of gadopentetate dimeglumine, Gd-DTPA, (Magnevist, Wayne, NJ) at 2 mL/sec (followed by a saline flush) via a power injector (Medrad, Warrendale, PA) after the acquisition of the first three dynamic scans (baseline). Results from a subset of data sets from this collection have been published (see below). If your use of this collection results in a publication, we would appreciate if you cite the appropriate references and acknowledge the award that supported collection and sharing of this dataset (U01 CA142565, PI Thomas E. Yankeelov).

本数据集收录了用于新辅助治疗背景下乳腺癌疗效评估研究的纵向正电子发射断层扫描/计算机断层扫描（PET/CT）与定量磁共振（MR）影像数据。
影像采集共设置三个时间节点：治疗开始前（t1）、第一周期治疗结束后（t2），以及第二周期治疗结束后或所有治疗完成前（手术前）（t3）。
PET/CT影像采用自研支撑装置采集，以使患者处于俯卧位，便于与磁共振影像进行配准。
本数据集的核心价值在于为乳腺癌治疗早期疗效评估的定量影像方法开发与验证提供临床影像数据。
本数据集由范德堡大学（Vanderbilt University）提供，项目负责人为Thomas E. Yankeelov博士。
PET/CT数据采用GE Discovery STE扫描仪（美国威斯康星州沃基肖市通用医疗（GE Healthcare））采集。采用低毫安CT扫描用于发射数据的衰减校正，透射CT扫描的采集参数如下：70kg体重患者的管电流为80 mAs，其余患者按体重比例缩放；管电压为120 KVp；螺距为1.675/1。
注射的氟代脱氧葡萄糖（FDG）活度对于70kg体重患者约为370 MBq（10 mCi），其余患者按体重比例调整。FDG经与患侧乳房对侧的肘前静脉静脉注射给药。
给药60分钟后，以3D模式采集发射数据，每个床位采集时长为2分钟。发射扫描首先以俯卧位仅采集乳腺区域，随后以仰卧位采集从颅顶至股骨中段的范围。
在t1和t3时间节点采集临床标准仰卧位影像及研究用俯卧位影像，而t2时间节点仅采集俯卧位影像。
磁共振影像数据包含弥散加权成像（DWI）、动态对比增强（DCE）影像以及用于T1映射的多翻转角数据。
磁共振扫描采用3.0T专用16通道双侧乳腺线圈（搭载MammoTrak检查床的飞利浦Achieva扫描仪）完成。
DWI采用单次激发自旋回波-平面回波成像（SE-EPI）序列，沿x、y、z三个正交方向施加弥散编码梯度。其中14例患者的DWI采用b值为0和500 s/mm²的序列，重复时间/回波时间（TR/TE）为2500 ms/45 ms，Δ=21.4 ms，δ=10.3 ms，共采集10次信号。19例患者采用b值为0和600 s/mm²的序列，TR/TE设为“最短”（范围1800~3083 ms/43~60 ms），Δ=20.7~29 ms，δ=11.4~21 ms，共采集10次信号。另有4例患者采用b值为50和600 s/mm²的序列，TR/TE设为“最短”（范围1840~3593 ms/43~60 ms），Δ=20.6~29 ms，δ=11.5~21 ms，共采集10次信号。
在动态对比增强磁共振（DCE-MRI）采集前，采用射频扰相3D梯度回波多翻转角序列采集T1映射所需数据，翻转角从2°到20°以2°为间隔共设置10个翻转角度。
T1映射与DCE扫描均采用以下参数：TR=7.9 ms，TE=4.6 ms，采集矩阵为192×192×20（覆盖全乳腺），矢状位方形视野为22 cm²，层厚5 mm。
DCE扫描中，每组20层影像的采集时长为16秒，共采集25个时间点，动态扫描总时长接近7分钟。
在前3次动态扫描（基线扫描）完成后，通过肘前静脉留置导管以2 mL/sec的流速经高压注射器（美国宾夕法尼亚州沃伦代尔市Medrad公司）推注0.1 mmol/kg的钆喷酸葡胺（Gd-DTPA，商品名Magnevist，新泽西州韦恩市），推注剂量为9~15 mL（依患者体重调整），推注后以生理盐水冲管。
本数据集部分子集的研究结果已发表（详见下文）。若您使用本数据集完成发表工作，请务必引用相关文献，并致谢支持本数据集采集与共享的资助项目（U01 CA142565，项目负责人Thomas E. Yankeelov）。